These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33860325)

  • 1. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of pharmacological target attainment with flucloxacillin and cefazolin in invasive methicillin-susceptible Staphylococcus aureus infection: a prospective cohort study in hospitalized patients.
    Campbell PO; Chin PKL; Dalton SC; Metcalf SCL; Douglas NM; Chambers ST
    Int J Antimicrob Agents; 2023 Jan; 61(1):106695. PubMed ID: 36464153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.
    Meenks SD; Punt N; le Noble JLML; Foudraine NA; Neef K; Janssen PKC
    Crit Care; 2023 Mar; 27(1):82. PubMed ID: 36869388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen.
    Wilkes S; van Berlo I; Ten Oever J; Jansman F; Ter Heine R
    Int J Antimicrob Agents; 2019 Mar; 53(3):310-317. PubMed ID: 30472288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.
    Jager NGL; van Hest RM; Xie J; Wong G; Ulldemolins M; Brüggemann RJM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2641-2649. PubMed ID: 32443147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia.
    Chin PKL; Drennan PG; Gardiner SJ; Zhang M; Dalton SC; Chambers ST; Begg EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2311-2316. PubMed ID: 29908071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis.
    Leder K; Turnidge JD; Korman TM; Grayson ML
    J Antimicrob Chemother; 1999 Jan; 43(1):113-8. PubMed ID: 10381108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue- Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations.
    Öbrink-Hansen K; Pham AD; Bue M; Hanberg P; Bendtsen M; Slater J; Friberg LE; Thorsted A; Stilling M
    Pharm Res; 2022 Jul; 39(7):1633-1643. PubMed ID: 35233728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis.
    Hartman SJF; Boeddha NP; Ekinci E; Koch BCP; Donders R; Hazelzet JA; Driessen GJ; de Wildt SN
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1255-1260. PubMed ID: 30968258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study.
    Henderson A; Harris P; Hartel G; Paterson D; Turnidge J; Davis JS; Tong SYC
    Int J Antimicrob Agents; 2019 Oct; 54(4):491-495. PubMed ID: 31181352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man.
    Fox E; Cheng V; Rawlins M; Dyer J; De Keulenaer B; Page MM; Hoad K; Roberts JA
    J Chemother; 2019; 31(7-8):419-423. PubMed ID: 31650900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.
    Abdul-Aziz MH; McDonald C; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Ann Pharmacother; 2014 Oct; 48(10):1380-4. PubMed ID: 24951308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
    Everts RJ; Begg R; Gardiner SJ; Zhang M; Turnidge J; Chambers ST; Begg EJ
    J Infect; 2020 Jan; 80(1):42-53. PubMed ID: 31521742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.